~~<i id='8E313CE601'><strike id='8E313CE601'><tt id='8E313CE601'><pre id='8E313CE601'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：focus 2025-10-02 04:02:53 Page View：2

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Scientists unlock the key to scar
Next article： Sports medicine is finally prioritizing gender equality

focus

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

With fresh data, a dynamic duo powers Eli Lilly to new heights

EliLillyCEODavidRicks(left)andChiefScientificOfficerDanielS.SkovronskyMollyFergusonforSTATThepartner

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

RaDonda Vaught to speak at CommonSpirit event on patient safety

RaDondaVaught,aformerVanderbiltUniversityMedicalCenternursechargedwithinthedeathofapatient,listensto

WSS

focus

focus

explore

focus

RaDonda Vaught to speak at CommonSpirit event on patient safety